New support program aims to help breast cancer patients stick with treatment
NCT ID NCT06983691
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a nurse-delivered patient navigation program for women with HER2+ metastatic breast cancer who are taking a specific combination of drugs. The program provides education, symptom management tips, and coping strategies over about 12 weeks. Researchers want to see if the program is feasible and acceptable to patients. Only 26 women will take part, and the main goal is to see if they find the program helpful and easy to use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Patient Navigation Program (behavioral intervention)
What this could lead to
If successful, this program could become a standard support tool to help women with HER2+ metastatic breast cancer better manage their treatment and symptoms.
What could go wrong
This is a very small, early feasibility study with only 26 participants. It tests whether the program is acceptable, not whether it improves health outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2+ METASTATIC BREAST CANCER (MBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••